These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

1671 related items for PubMed ID: 19395154

  • 1. Long-term efficacy of maintenance bacillus Calmette-Guérin versus maintenance mitomycin C instillation therapy in frequently recurrent TaT1 tumours without carcinoma in situ: a subgroup analysis of the prospective, randomised FinnBladder I study with a 20-year follow-up.
    Järvinen R, Kaasinen E, Sankila A, Rintala E, FinnBladder Group.
    Eur Urol; 2009 Aug; 56(2):260-5. PubMed ID: 19395154
    [Abstract] [Full Text] [Related]

  • 2. Long-term results of maintenance treatment of mitomycin C or alternating mitomycin C and bacillus Calmette-Guérin instillation therapy of patients with carcinoma in situ of the bladder: a subgroup analysis of the prospective FinnBladder 2 study with a 17-year follow-up.
    Järvinen R, Kaasinen E, Rintala E, Group TF.
    Scand J Urol Nephrol; 2012 Dec; 46(6):411-7. PubMed ID: 22746387
    [Abstract] [Full Text] [Related]

  • 3. Long-term outcome of patients with frequently recurrent non-muscle-invasive bladder carcinoma treated with one perioperative plus four weekly instillations of mitomycin C followed by monthly bacillus Calmette-Guérin (BCG) or alternating BCG and interferon-α2b instillations: prospective randomised FinnBladder-4 study.
    Järvinen R, Marttila T, Kaasinen E, Rintala E, Aaltomaa S, Kallio J, Liukkonen T, Puolakka VM, Seppänen M, Tuhkanen K, Vaarala M, Viitanen J, Boström PJ, FinnBladder Group.
    Eur Urol; 2015 Oct; 68(4):611-7. PubMed ID: 25748117
    [Abstract] [Full Text] [Related]

  • 4. An individual patient data meta-analysis of the long-term outcome of randomised studies comparing intravesical mitomycin C versus bacillus Calmette-Guérin for non-muscle-invasive bladder cancer.
    Malmström PU, Sylvester RJ, Crawford DE, Friedrich M, Krege S, Rintala E, Solsona E, Di Stasi SM, Witjes JA.
    Eur Urol; 2009 Aug; 56(2):247-56. PubMed ID: 19409692
    [Abstract] [Full Text] [Related]

  • 5. Intravesical bacille Calmette-Guérin versus mitomycin C in superficial bladder cancer: formal meta-analysis of comparative studies on tumor progression.
    Böhle A, Bock PR.
    Urology; 2004 Apr; 63(4):682-6; discussion 686-7. PubMed ID: 15072879
    [Abstract] [Full Text] [Related]

  • 6. Update on the Dutch Cooperative Trial: mitomycin versus bacillus Calmette-Guérin-Tice versus bacillus Calmette-Guérin RIVM in the treatment of patients with pTA-pT1 papillary carcinoma and carcinoma in situ of the urinary bladder. Dutch South East Cooperative Urological Group.
    Witjes WP, Witjes JA, Oosterhof GO, Debruyne MJ.
    Semin Urol Oncol; 1996 Feb; 14(1 Suppl 1):10-6. PubMed ID: 8727805
    [Abstract] [Full Text] [Related]

  • 7. Analysis of progression and survival after 10 years of a randomized prospective study comparing mitomycin-C and bacillus Calmette-Guérin in patients with high-risk bladder cancer.
    Gårdmark T, Jahnson S, Wahlquist R, Wijkström H, Malmström PU.
    BJU Int; 2007 Apr; 99(4):817-20. PubMed ID: 17244282
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Bacillus Calmette-Guerin versus epirubicin for primary, secondary or concurrent carcinoma in situ of the bladder: results of a European Organization for the Research and Treatment of Cancer--Genito-Urinary Group Phase III Trial (30906).
    de Reijke TM, Kurth KH, Sylvester RJ, Hall RR, Brausi M, van de Beek K, Landsoght KE, Carpentier P, European Organization for the Research and Treatment of Cancer-Genito-Urinary Group.
    J Urol; 2005 Feb; 173(2):405-9. PubMed ID: 15643181
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Can early single dose instillation of epirubicin improve bacillus Calmette-Guerin efficacy in patients with nonmuscle invasive high risk bladder cancer? Results from a prospective, randomized, double-blind controlled study.
    Cai T, Nesi G, Tinacci G, Zini E, Mondaini N, Boddi V, Mazzoli S, Bartoletti R.
    J Urol; 2008 Jul; 180(1):110-5. PubMed ID: 18485394
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Patterns of recurrence and outcomes following induction bacillus Calmette-Guerin for high risk Ta, T1 bladder cancer.
    Lerner SP, Tangen CM, Sucharew H, Wood D, Crawford ED.
    J Urol; 2007 May; 177(5):1727-31. PubMed ID: 17437798
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Twelve-year follow up of a randomized prospective trial comparing bacillus Calmette-Guerin and epirubicin as adjuvant therapy in superficial bladder cancer.
    Cheng CW, Chan SF, Chan LW, Chan CK, Ng CF, Cheung HY, Chan SY, Wong WS, Lai FM, To KF, Li ML.
    Int J Urol; 2005 May; 12(5):449-55. PubMed ID: 15948743
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Adjuvant intravesical instillation for primary T1G3 bladder cancer: BCG versus MMC in Korea.
    Cho IC, Kim EK, Joung JY, Seo HK, Chung J, Park WS, Lee KH.
    Anticancer Res; 2012 Apr; 32(4):1493-8. PubMed ID: 22493392
    [Abstract] [Full Text] [Related]

  • 20. [Bacillus of Calmette-Guérin immunotherapy: which protocol?].
    Saint F.
    Prog Urol; 2008 May; 18 Suppl 5():S99-104. PubMed ID: 18585635
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 84.